Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Atrial natriuretic peptide receptor 2 (NPR2), also known as natriuretic peptide receptor B (NPR-B) or guanylate cyclase B (GC-B), is a membrane-bound receptor that primarily binds C-type natriuretic peptide (CNP). Upon ligand binding, it catalyzes the conversion of GTP to cGMP, a second messenger involved in skeletal growth regulation and potentially other homeostatic processes. Mutations in the NPR2 gene can lead to skeletal dysplasias.
Guanylate cyclase activation leading to increased cGMP production
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Atrial Natriuretic Peptide Receptor 2 (NPR2).